Clinical trial
Sacituzumab Govitecan in Patients With Metastatic Castration-Resistant Prostate Cancer Progressing on Second Generation AR-Directed Therapy
NCT03725761
Study timeline
Study start (actual)2018-10-24Date precision: day
Registry last updated2026-06-04
Observed by CureCurrent2026-10-07
Recorded dates are source observations, not predictions. Missing milestones are not estimated.
Conditions
Prostate Cancerunresolved
Interventions
Sacituzumab GovitecanDRUG · verified · RxNorm: sacituzumab govitecan
Sponsors & collaborators
University of Wisconsin, Madisonlead sponsor
National Cancer Institute (NCI)collaborator
Gilead Sciencescollaborator
Mapped research locations
Registry source
Open the source record to verify current eligibility, contacts, locations and registry updates.
Open NCT03725761 on ClinicalTrials.gov ↗Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.